Albireo Exits NASH, But Has Best-In-Class IBAT Opportunity

Albireo Pharma, Inc. has determined that although its non-alcoholic steatohepatitis (NASH) candidate elobixibat reduced LDL cholesterol at statistical significance compared to placebo in a Phase II study, it is not continuing study of that drug in NASH because its overall therapeutic profile is “unremarkable.”

So even with a study that hit its primary endpoint, Albireo’s NASH program amounts to another setback in that disease, which has seen numerous clinical and regulatory disappointments this year....